General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Here's Why Merck (MRK) is a Strong Momentum Stock | zacks.com • |
Here's Why Merck (MRK) is a Strong Momentum Stock | news.google.com • |
Here's Why Merck (MRK) is a Strong Momentum Stock | news.google.com • |
Here's Why Merck (MRK) is a Strong Momentum Stock | news.google.com • |
Biotech Stocks: The Top 5 To Watch As Shares Trend Down | news.google.com • |
Best Healthcare Stocks of May 2024 – Forbes Advisor | news.google.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-04-25 | 2024-03 | 1.94 | 2.07 | 0.13 | 6.70% |
2024-02-01 | 2023-12 | -0.09 | 0.03 | 0.12 | 133.33% |
2023-10-26 | 2023-09 | 1.94 | 2.13 | 0.19 | 9.79% |
2023-08-01 | 2023-06 | -2.17 | -2.06 | 0.11 | 5.07% |
2023-04-27 | 2023-03 | 1.34 | 1.4 | 0.06 | 4.48% |
2023-02-02 | 2022-12 | 1.56 | 1.62 | 0.06 | 3.85% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-10-10 | Morgan Stanley | Upgrade | Equal-Weight | Equal-Weight |
2023-10-05 | Truist Securities | Upgrade | Buy | Buy |
2023-10-03 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-10-01 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-09-04 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-08-21 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-01-21 | CHATTOPADHYAY SANAT | Officer | 157.19K | Stock Award(Grant) |
2024-02-13 | DAVIS ROBERT M | Chief Executive Officer | 348.33K | Sale |
2024-01-21 | DELUCA RICHARD ROBERT JR. | Officer | 137.01K | Stock Award(Grant) |
2024-02-08 | LI DEAN Y | Officer | 46.24K | Sale |
2024-02-13 | LITCHFIELD CAROLINE | Chief Financial Officer | 50.91K | Sale |
2024-02-01 | MIZELL STEVEN CRAIG | Officer | 23.62K | Sale |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Group Inc | 243.64M | 28.11B | 9.60% |
2023-06-29 | Blackrock Inc. | 205.65M | 23.73B | 8.10% |
2023-06-29 | State Street Corporation | 118.56M | 13.68B | 4.67% |
2023-06-29 | Wellington Management Group, LLP | 77.25M | 8.91B | 3.04% |
2023-06-29 | Geode Capital Management, LLC | 52.72M | 6.08B | 2.08% |
2023-06-29 | FMR, LLC | 38.96M | 4.50B | 1.54% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 79.16M | 9.13B | 3.12% |
2023-06-29 | Vanguard 500 Index Fund | 60.41M | 6.97B | 2.38% |
2023-05-30 | Fidelity 500 Index Fund | 28.37M | 3.13B | 1.12% |
2023-08-30 | SPDR S&P 500 ETF Trust | 27.96M | 3.05B | 1.10% |
2023-08-30 | iShares Core S&P 500 ETF | 23.73M | 2.59B | 0.94% |
2023-06-29 | Vanguard Index-Value Index Fund | 22.05M | 2.54B | 0.87% |
Dividend | Date |
---|---|
0.77 | 2024-03-14 |
0.77 | 2023-12-14 |
0.73 | 2023-09-14 |
0.73 | 2023-06-14 |
0.73 | 2023-03-14 |
0.73 | 2023-01-09 |
Split | Date |
---|---|
1048 : 1000 | 2021-06-03 |
2 : 1 | 1999-02-17 |
3 : 1 | 1992-05-26 |
3 : 1 | 1988-05-26 |
2 : 1 | 1986-05-27 |
2 : 1 | 1972-06-01 |
https://cryptohedgehog.blogspot.com/2020/11/16-november-2020-covids-economy-are-you.html
With market and economy downturn in March, how many stocks truly recovered ?
Finally a chance to check vaccine results!! Sept 27th mark your calendar!! GO BNTX/PFE! https://www.google.com/amp/s/www.bloombergquint.com/amp/coronavirus-outbreak/pfizer-s-covid-vaccine-trial-plan-may-beat-rivals-to-early-look
$SAVA - A second opinion
*
If you have been following Cassava and their Alzheimers drug PTI-125, you will know that 1 of 2 trial endpoints was not recently met, sending the stock down almost 80%. But, I think the exodus was premature. Here is why:
Per the companys press release, one endpoint WAS MET:
A secondary endpoint of CSF levels of IL1-beta, a core biomarker of neuroinflammation from baseline to day 28, was met, Cassava said. The drug was also found to be safe and well-tolerated.
Per NIH, neuro inflammation is the CORE issue with Alzheimers:
Inflammation in Alzheimer's disease (AD) has emerged as a central pathology that likely plays a role in onset and progression of the disease
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214864/
Cycling back to Cassavas press release, they state:
CSF levels of IL1-beta, a core biomarker of neuroinflammation ... was met
To reiterate the NIH definition, Neuro Inflammation is core to the onset and progression of Alzheimers. At some point, Cassava IS going to cycle back around to the secondary endpoint (neuro inflammation), and realize that ALONE constitutes an ALZHEIMER DRUG THAT WORKS.
In this case, traders were SO tuned into the word miss that they MISSED something EXTREMELY IMPORTANT -> The efficacy of PTI-125 towards Neuro Inflammation, in Alzheimers (ALONE), makes it A BLOCKBUSTER DRUG!
$SAVA - A second opinion
*
If you have been following Cassava and their Alzheimers drug PTI-125, you will know that 1 of 2 trial endpoints was not recently met, sending the stock down almost 80%. But, I think the exodus was premature. Here is why:
Per the companys press release, one endpoint WAS MET:
A secondary endpoint of CSF levels of IL1-beta, a core biomarker of neuroinflammation from baseline to day 28, was met, Cassava said. The drug was also found to be safe and well-tolerated.
Per NIH, neuro inflammation is the CORE issue with Alzheimers:
Inflammation in Alzheimer's disease (AD) has emerged as a central pathology that likely plays a role in onset and progression of the disease
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214864/
Cycling back to Cassavas press release, they state:
CSF levels of IL1-beta, a core biomarker of neuroinflammation ... was met
To reiterate the NIH definition, Neuro Inflammation is core to the onset and progression of Alzheimers. At some point, Cassava IS going to cycle back around to the secondary endpoint (neuro inflammation), and realize that ALONE constitutes an ALZHEIMER DRUG THAT WORKS.
In this case, traders were SO tuned into the word miss that they MISSED something EXTREMELY IMPORTANT. The efficacy of PTI-125 towards Neuro Inflammation, in Alzheimers (ALONE), makes it A BLOCKBUSTER DRUG!
high capital, high volume, great earning report, why still cheap ?
I thought this company sell oil , not medicines. Lol
This is a steal
How about if the House do not wanna pay you! It is the game but the House always win. Fuck it!
This is just pump and dump. Remember they sell medicines not oil and gas. The whole world need a lot medicines for treatments not only Coronavirus but only the others diseases because short if supply and increase of the demand. The company just dont want to pay you, the investor and they say cuts. That is it!
A lot companies buy puts before earning and dump it hard, take all money from other side. Dirty!